Asbestos and the lung in the 21st century: An update

Clinical Respiratory Journal

Volumn 8, Issue 1, 2014, Pages 1-10

  Prazakova, Silvie ^a,b   Thomas, Paul S ^a,b   Sandrini, Alessandra ^c   Yates, Deborah H ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Asbestos; Asbestosis; Diffuse pleural thickening; Epidemiology; Exposure; Mesothelioma; Pleural plaques

Indexed keywords

ASBESTOS;

ARTICLE; ASBESTOS RELATED DISORDER; ASBESTOSIS; ATELECTASIS; BENIGN ASBESTOS PLEURAL EFFUSION; BLESOVSKYS SYNDROME; CLINICAL FEATURE; DRUG INDUCED DISEASE; HUMAN; LATENT PERIOD; LUNG CANCER; MALIGNANT MESOTHELIOMA; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PLEURA PLAQUE; PLEURA THICKENING; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE;

ASBESTOS; ASBESTOSIS; DIFFUSE PLEURAL THICKENING; EPIDEMIOLOGY; EXPOSURE; MESOTHELIOMA; PLEURAL PLAQUES;

ASBESTOSIS; DEVELOPING COUNTRIES; HUMANS; LUNG DISEASES; MESOTHELIOMA; OCCUPATIONAL EXPOSURE; PLEURA; PLEURAL EFFUSION; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891833904     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12028     Document Type: Article

References (73)

1. Ramazzini C. Asbestos is still with us: repeat call for a universal ban. Am J Ind Med. 2011;54(2): 168-173.
2. Kanarek MS. Mesothelioma from chrysotile asbestos: update. Ann Epidemiol. 2011;21(9): 688-697.
3. The World Health Organization. Asbestos: elimination of asbestos-related diseases. Fact sheet N°343. 2010. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/Mesothelioma/incidence/#source6 (accessed 25 Jan 2013).
4. Cancer Research UK. Mesothelioma incidence statistics. 2012. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/Mesothelioma/incidence/#source6 (accessed 25 Mar 2013).
5. Tan E, Warren N, Darnton AJ, Hodgson JT. Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer. 2010;103(3): 430-436.
6. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health. 2003;9(3): 206-217.
7. Safe Work Australia. Australian mesothelioma registry 1st annual report. Cancer Institute NSW, Camberra. 2011. Available at: http://www.mesothelioma-australia.com/publications.aspx (accessed 20 Feb 2013).
8. Clements M, Berry G, Shi J, Ware S, Yates D, Johnson A. Projected mesothelioma incidence in men in New South Wales. Occup Environ Med. 2007;64(11): 747-752.
9. Howlader N, Noone AM, Krapcho M, etal. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). National Cancer Institute, Bethesda, MD. 2012. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/ (accessed 5 Jan 2013).
10. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39(7): 576-588.
11. Park EK, Takahashi K, Hoshuyama T, Cheng TJ, Delgermaa V, Le GV, Sorahan, T. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4): 514-518.
12. Donovan EP, Donovan BL, McKinley MA, Cowan DM, Paustenbach DJ. Evaluation of take home (para-occupational) exposure to asbestos and disease: a review of the literature. Crit Rev Toxicol. 2012;42(9): 703-731.
13. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer. 2009;100(7): 1175-1183.
14. Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect. 2007;115(10): 1401-1405.
15. Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, Shilkin K, Musk AW. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust. 2011;195(5): 271-274.
16. Roggli VL, Gibbs AR, Attanoos R, etal. Pathology of asbestosis- An update of the diagnostic criteria: report of the asbestosis committee of the college of american pathologists and pulmonary pathology society. Arch Pathol Lab Med. 2010;134(3): 462-480.
17. American Thoracic Society. A diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6): 691-715.
18. Lazarus AA, Philip A. Asbestosis. Dis Mon. 2011;57(1):14-26.
19. International Labour Office. Guidelines for the use of the ILO international classification of radiographs of pneumoconioses, revised edition 2011. Geneva. 2011.
20. Kipen HM, Lilis R, Suzuki Y, Valciukas JA, Selikoff IJ. Pulmonary fibrosis in asbestos insulation workers with lung cancer: a radiological and histopathological evaluation. Br J Ind Med. 1987;44(2): 96-100.
21. Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med. 1978;298(17): 934-939.
22. Akira M, Yamamoto S, Inoue Y, High-resolution SM. CT of asbestosis and idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2003;181(1): 163-169.
23. Dalichau S, Demedts A, im Sande A, Moller T. Improvement of lasting effects in outpatient pulmonary rehabilitation with special regard to exercise therapy and sports. Rehabilitation (Stuttg). 2010;49(1): 30-37.
24. Ochmann U, Kotschy-Lang N, Raab W, Kellberger J, Nowak D, Jorres RA. Long-term efficacy of pulmonary rehabilitation in patients with occupational respiratory diseases. Respiration. 2012;84(5): 396-405.
25. Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos pleural diseases. Curr Opin Pulm Med. 2003;9(4): 266-271.
26. Roach HD, Davies GJ, Attanoos R, Crane M, Adams H, Phillips S. Asbestos: when the dust settles an imaging review of asbestos-related disease. Radiographics. 2002;22: Spec No: S167-184.
27. Huggins JT, Sahn SA. Causes and management of pleural fibrosis. Respirology. 2004;9(4): 441-447.
28. Clin B, Paris C, Ameille J, etal. Do asbestos-related pleural plaques on HRCT scans cause restrictive impairment in the absence of pulmonary fibrosis? Thorax. 2011;66(11): 985-991.
29. Mukherjee S, de Klerk N, Palmer LJ, Olsen NJ, Pang SC, Musk AW. Chest pain in asbestos-exposed individuals with benign pleural and parenchymal disease. Am J Respir Crit Care Med. 2000;162(5): 1807-1811.
30. Park EK, Thomas PS, Wilson D, Choi HJ, Johnson AR, Yates DH. Chest pain in asbestos and silica-exposed workers. Occup Med (Lond). 2011;61(3): 178-183.
31. British Thoracic Society. Pleural plaques - information for health care professionals. 2011. Available at: http://www.brit-thoracic.org.uk/Portals/0/Guidelines/Malignant%20Mesothelioma/299912_PleuralPlaques_acc.pdf (accessed 20 Jan 2013).
32. Hillerdal G, Ozesmi M. Benign asbestos pleural effusion: 73 exudates in 60 patients. Eur J Respir Dis. 1987;71(2): 113-121.
33. Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA. 1982;247(5): 617-622.
34. Yates DH, Browne K, Stidolph PN, Neville E. Asbestos-related bilateral diffuse pleural thickening: natural history of radiographic and lung function abnormalities. Am J Respir Crit Care Med. 1996;153(1): 301-306.
35. Miles SE, Sandrini A, Johnson AR, Yates DH. Clinical consequences of asbestos-related diffuse pleural thickening: a review. J Occup Med Toxicol. 2008;3: 20-30.
36. Hannaford-Turner K, Elder D, Sim MR, Abramson MJ, Johnson AR, Yates DH. Surveillance of Australian workplace based respiratory events (SABRE) in New South Wales. Occup Med. 2010;60(5): 376-382.
37. Jeebun V, Stenton SC. The presentation and natural history of asbestos-induced diffuse pleural thickening. Occup Med. 2012;62(4): 266-268.
38. Kee ST, Gamsu G, Blanc P. Causes of pulmonary impairment in asbestos-exposed individuals with diffuse pleural thickening. Am J Respir Crit Care Med. 1996;154(3 Pt. 1): 789-793.
39. Lynch DA, Gamsu G, Aberle DR. Conventional and high resolution computed tomography in the diagnosis of asbestos-related diseases. Radiographics. 1989;9(3): 523-551.
40. Hillerdal G. Rounded atelectasis. Clinical experience with 74 patients. Chest. 1989;95(4): 836-841.
41. Batra P, Brown K, Hayashi K, Mori M. Rounded atelectasis. Journal of Thorac Imaging. 1996;11(3): 187-197.
42. British Thoracic Society. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(Suppl. 2): ii1-ii19.
43. Musk AW, Olsen N, Alfonso H, etal. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38(6): 1420-1424.
44. Fuhrer G, Lazarus AA. Mesothelioma. Dis Mon. 2011;57(1): 40-54.
45. Scherpereel A, Astoul P, Baas P, etal. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3): 479-495.
46. Sharif S, Zahid I, Routledge T, Scarci M. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12(5): 806-811.
47. Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2010;13(5): 801-811.
48. Pilling J, Dartnell JA, Lang-Lazdunski L. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg. 2010;58(4): 215-219.
49. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: malignant pleural mesothelioma. NCCN. 2013.
50. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108(4): 1122-1128.
51. Wheatley-Price P, Yang B, Patsios D, etal. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010;28(20): 3316-3322.
52. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178(8): 832-837.
53. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbon M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353(15): 1564-1573.
54. Park EK, Thomas PS, Johnson AR, Yates DH. Osteopontin levels in an asbestos-exposed population. Clin Cancer Res. 2009;15(4): 1362-1366.
55. Pass HI, Levin SM, Harbut MR, etal. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15): 1417-1427.
56. Watzka SB, Posch F, Pass HI, Flores RM, Hannigan GE, Bernhard D, Weber M, Mueller MR. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure. Eur J Cardiothorac Surg. 2013;43(5): 940-945.
57. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers. 2012;32(2): 123-131.
58. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 2008;3(8): 851-857.
59. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13(10): 2928-2935.
60. Chapman EA, Thomas PS, Stone E, Lewis C, Yates DH. A breath test for malignant mesothelioma using an electronic nose. Eur Respir J. 2012;40(2): 448-454.
61. Kirschner MB, Cheng YY, Badrian B, etal. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(7): 1184-1191.
62. Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011;32(1): 102-110.
63. Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest. 1995;107(5): 1454-1456.
64. Treasure T, Lang-Lazdunski L, Waller D, etal. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8): 763-772.
65. de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura - a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43(3): 511-516.
66. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28): 6881-6889.
67. Vogelzang NJ, Rusthoven JJ, Symanowski J, etal. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14): 2636-2644.
68. Henderson DW, Rodelsperger K, Woitowitz HJ, Leigh J. After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004. Pathology. 2004;36(6): 517-550.
69. Frost G, Darnton A, Harding AH. The effect of smoking on the risk of lung cancer mortality for asbestos workers in Great Britain (1971-2005). Ann Occup Hyg. 2011;55(3): 239-247.
70. Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev. 2013;39(5): 498-506.
71. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13(71): 287-297.
72. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5): 395-409.
73. Vierikko T, Jarvenpaa R, Autti T, etal. Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. Eur Respir J. 2007;29(1): 78-84.